 |
71 Diseases |  |
105 Trials |
|
105 Trials |  |
2830 News |  |
| «12...56789101112131415...3738» |
- | Halaven (eribulin mesylate) / Eisai
Journal: A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin B. (Pubmed Central) - Aug 13, 2022
These syntheses, together with our previous work on the total syntheses of halichondrin B and norhalichondrin B, demonstrate and validate the powerful reverse approach in the construction of cyclic ether structural motifs. On the other hand, the unified synthetic strategy for the synthesis of the related macrolactam analog provides inspiration and opportunities in the halichondrin field and related polycyclic ether areas.
- || Halaven (eribulin mesylate) / Eisai
#hypoxia #antiangiogenic #antiestrogen #microangipathic #hemolytic #hematoma #ductalcarcinoma #medullary #mucinous #progestrone #lumpectomy #masectomy #radiation #lymphedema #inherited #mutations #covid19 #eribulin #CEA #SNP #genetic #event #ASCO22 #news #Livestream (Twitter) - Aug 6, 2022
- || Halaven (eribulin mesylate) / Eisai
P2 data, Journal, Combination therapy: Phase II clinical trial of Eribulin-gemcitabine combination therapy in previously treated patients with advanced liposarcoma or leiomyosarcoma. (Pubmed Central) - Aug 6, 2022
Eribulin-gemcitabine combination therapy showed promising activity and an acceptable safety profile in patients with liposarcoma or leiomyosarcoma. Gene expression profiling with pathway enrichment analysis would have possibilities to have predictive value for survival outcome, necessitating further investigation to confirm.
- ||| Halaven (eribulin mesylate) / Eisai
Trial completion, Enrollment change, Combination therapy: Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer (clinicaltrials.gov) - Aug 4, 2022
P1/2, N=98, Completed, Sponsor: Eisai Inc.
Gene expression profiling with pathway enrichment analysis would have possibilities to have predictive value for survival outcome, necessitating further investigation to confirm. Unknown status --> Completed | N=150 --> 98
- | Halaven (eribulin mesylate) / Eisai
Journal: Acute-on-chronic liver failure following eribulin treatment for metastatic breast cancer: a case report. (Pubmed Central) - Jul 29, 2022
The patient was diagnosed with ACLF induced by eribulin. Therefore, ACLF may be a lethal and rare adverse event when patients with chronic liver metastases receive eribulin treatment, and clinicians' awareness should be increased for optimal prevention and prompt diagnosis and treatment.
- datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca
Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators' choice of chemotherapy (ICC) in previously-treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR+/HER2–) breast cancer: TROPION-Breast01 (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2362;
P1, P3
Pts are stratified by number of prior chemotherapy lines, prior CDK4/6 inhibitor use, and region. Enrolment is ongoing.
- Halaven (eribulin mesylate) / Eisai, Focus V (anlotinib) / Advenchen, Sino Biopharm
Eribulin combined with anlotinib for patients with HER2-negative metastatic breast cancer: A single-arm, multicenter, phase II study (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2355;
P2
Conclusions The combination of eribulin and anlotinib improved the survival of HER2-negative metastatic breast cancer patients and showed tolerable toxicities. Further studies enrolling more patients are still needed.
- Halaven (eribulin mesylate) / Eisai
Efficacy of eribulin mesylate in HER2-low metastatic breast cancer (MBC): Results from three phase III studies (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2216;
P3
HR, hazard ratio; NE, not estimable. Conclusions Eribulin had efficacy regardless of HER2 status, and, in HER2-low pts, had similar or numerically superior outcomes vs chemotherapy in each study..
- Halaven (eribulin mesylate) / Eisai
Eribulin (E) plus endocrine therapy (ET) in patients (pts) with HR[+]/HER2[-] metastatic breast cancer (mBC) after progression on previous ET: The REVERT study (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_2148;
P2
All grade and grade ≥3 adverse events were similar in both arms, being neutropenia and fatigue the most frequent. Conclusions Although superiority of E+AI over E single therapy seems unlikely in this scenario, E+AI combination deserves further investigation in pts with ET-resistant, HR[+]/HER2[-] mBC, after progression to CDK4/6 inhibitors.
- |||| Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) - Jul 28, 2022
P3, N=270, Recruiting, Sponsor: Prof. W. Janni
Conclusions Although superiority of E+AI over E single therapy seems unlikely in this scenario, E+AI combination deserves further investigation in pts with ET-resistant, HR[+]/HER2[-] mBC, after progression to CDK4/6 inhibitors. Trial completion date: Jun 2023 --> Nov 2024 | Trial primary completion date: Sep 2021 --> Sep 2024
- | Halaven (eribulin mesylate) / Eisai, Kisqali (ribociclib) / Novartis
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Tumor cell, Metastases: DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). (clinicaltrials.gov) - Jul 28, 2022
P2, N=116, Active, not recruiting, Sponsor: Prof. W. Janni
Trial completion date: Jun 2023 --> Nov 2024 | Trial primary completion date: Sep 2021 --> Sep 2024 Recruiting --> Active, not recruiting | N=300 --> 116 | Trial completion date: Dec 2022 --> Dec 2024 | Trial primary completion date: Dec 2020 --> Dec 2024
- | Halaven (eribulin mesylate) / Eisai
Journal: The interaction of spongistatin 1 with tubulin. (Pubmed Central) - Jul 28, 2022
Little inhibition also occurred with the peptides dolastatin 15, its active pentapeptide derivative, vitilevuamide, or diazonamide A, nor with the vinca alkaloid vinblastine...Spongistatin 5 was found to be a competitive inhibitor of [H]spongistatin 1 binding, with an apparent K of 2.2 μM. We propose that the strong picomolar cytotoxicity of spongistatin 1 probably derives from its extremely tight binding to tubulin.
- ||| Onzeald (etirinotecan pegol) / Nektar Therap
Clinical, P3 data, Journal: Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. (Pubmed Central) - Jul 27, 2022
P3
However, this study represents one of the largest published trials dedicated to patients with breast cancer and BM and may help to inform further research. ClinicalTrials.gov Identifier: NCT02915744.
- Halaven (eribulin mesylate) / Eisai
Immune and vascular biomarkers associated with efficacy and mechanism of actions of the combination of lenvatinib (L) and eribulin (E) in leiomyosarcoma (LMS) and liposarcoma (LPS) (7.3.U - Urval Auditorium) - Jul 25, 2022 - Abstract #ESMO2022ESMO_1823;
P1/2
Conclusions L+E may have the ability to adjust the TME. A pre-treatment immune-suppressive TME was associated with worse clinical efficacy, but pts with a transformed immune-active post-treatment TME after L + E were associated with better outcome.
- Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead
Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) by HER2 immunohistochemistry (IHC) status in the phase III TROPiCS-02 study (7.2.E - Évry Auditorium) - Jul 25, 2022 - Abstract #ESMO2022ESMO_1595;
P3
Conclusions Clinical benefit with SG vs TPC in HER2 IHC0 and HER2-Low HR+/HER2- MBC was consistent with that of the TROPiCS-02 ITT population. SG should be considered an effective treatment option for pts with HR+/HER2- MBC, regardless of HER2 status.
- Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead
Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2- metastatic breast cancer (MBC) (7.3.U - Urval Auditorium) - Jul 25, 2022 - Abstract #ESMO2022ESMO_1565;
P3
Table: 1553O EORTC QLQ-C30 least-square mean change from baseline SG, sacituzumab govitecan; TPC, treatment of physician's choice. Conclusions Despite the association with worsening diarrhea, SG demonstrated an overall HRQoL benefit in heavily-pretreated patients with HR+/HER2- MBC.
- ||| Jivadco (trastuzumab duocarmazine) / Byondis, Medac
Trial completion date, Metastases: TULIP: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Jul 25, 2022
P3, N=436, Active, not recruiting, Sponsor: Byondis B.V.
Conclusions Despite the association with worsening diarrhea, SG demonstrated an overall HRQoL benefit in heavily-pretreated patients with HR+/HER2- MBC. Trial completion date: May 2022 --> Oct 2022
- | Halaven (eribulin mesylate) / Eisai, eribulin liposomal (E7389-LF) / Eisai
Journal: Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer. (Pubmed Central) - Jul 24, 2022
Trial completion date: May 2022 --> Oct 2022 E7389-LF 2.0 mg/m every 3 weeks was well tolerated for the treatment of several different tumor types, and larger studies in these populations are warranted.
- | Halaven (eribulin mesylate) / Eisai
Journal: Computational study of interactions of anti-cancer drug eribulin with human tubulin isotypes. (Pubmed Central) - Jul 17, 2022
The β-tubulin isotype, which shows low sensitivity to eribulin in experimental results, had the least binding affinity in the system αβ complex and the average binding affinity in the system αβ among all 14 systems. Additionally, we performed steered MD simulations and DynDom analysis of the systems with the lowest binding energy (αβ) and the highest binding energy (αβ) and extracted force, displacement, and H-bonding profiles during the pulling simulations to get a better insight.
- | Halaven (eribulin mesylate) / Eisai
Biomarker, Journal: Complete Response to Eribulin in a Patient with Unresectable Liposarcoma: A Case Report and the Implications of New Biomarkers. (Pubmed Central) - Jul 14, 2022
Additionally, we performed steered MD simulations and DynDom analysis of the systems with the lowest binding energy (αβ) and the highest binding energy (αβ) and extracted force, displacement, and H-bonding profiles during the pulling simulations to get a better insight. No abstract available
- || Trial completion date, Trial initiation date, Trial primary completion date: SMMART Adaptive Clinical Treatment (ACT) Trial (clinicaltrials.gov) - Jul 14, 2022
P2, N=131, Not yet recruiting, Sponsor: OHSU Knight Cancer Institute
No abstract available Trial completion date: Mar 2025 --> Mar 2026 | Initiation date: Apr 2022 --> Dec 2022 | Trial primary completion date: Mar 2025 --> Mar 2026
- || Tukysa (tucatinib) / Pfizer, Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche
New P2 trial, Combination therapy, Metastases: Tucatinib+Trastuzumab+Eribulin in HER2+ MBC (clinicaltrials.gov) - Jul 14, 2022
P2, N=30, Not yet recruiting, Sponsor: Criterium, Inc.
- || Halaven (eribulin mesylate) / Eisai
Trial completion, Combination therapy, Metastases: A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients (clinicaltrials.gov) - Jul 14, 2022
P1, N=19, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Mar 2025 --> Mar 2026 | Initiation date: Apr 2022 --> Dec 2022 | Trial primary completion date: Mar 2025 --> Mar 2026 Active, not recruiting --> Completed
- ||| Halaven (eribulin mesylate) / Eisai
Trial completion: IRENE: Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (clinicaltrials.gov) - Jul 13, 2022
P=N/A, N=353, Completed, Sponsor: Eisai GmbH
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Halaven (eribulin mesylate) / Eisai
Biomarker, Retrospective data, Journal, PD(L)-1 Biomarker, IO biomarker: B Lymphocytes Are a Predictive Marker of Eribulin Response and Overall Survival in Locally Advanced or Metastatic Breast Cancer: A Multicenter, Two-Cohort, Non-Randomized, Open-Label, Retrospective Study. (Pubmed Central) - Jul 13, 2022
Seven-color multiplex immunofluorescence was used to phenotype lymphocytes in the primary tumor. It has been shown that the PD1-negative-to-PD1-positive B cells ratio in primary tumors more than 3 is an independent predictor of the short-term effectiveness of eribulin [OR (95%CI) 14.09 (1.29-153.35), p=0.0029] and worse overall survival [HR (95%CI) 11.25 (1.37-70.25), p=0.0009] in patients with locally advanced or metastatic triple-negative breast cancer.
- | Halaven (eribulin mesylate) / Eisai
Trial primary completion date: A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer (clinicaltrials.gov) - Jul 12, 2022
P2, N=22, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
It has been shown that the PD1-negative-to-PD1-positive B cells ratio in primary tumors more than 3 is an independent predictor of the short-term effectiveness of eribulin [OR (95%CI) 14.09 (1.29-153.35), p=0.0029] and worse overall survival [HR (95%CI) 11.25 (1.37-70.25), p=0.0009] in patients with locally advanced or metastatic triple-negative breast cancer. Trial primary completion date: May 2022 --> Dec 2022
- | Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, Votrient (pazopanib) / Novartis, Halaven (eribulin mesylate) / Eisai
Retrospective data, Journal: Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma. (Pubmed Central) - Jul 8, 2022
Our exploratory study revealed that the response rate of second-line chemotherapy regimens for patients with SS was 9.4%. Therefore, there is an urgent need to develop more active therapeutic regimens for SSs.
- ||| Halaven (eribulin mesylate) / Eisai
Retrospective data, Journal, Adverse events: Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment. (Pubmed Central) - Jul 8, 2022
Age ≥65 years was also associated with SAE occurrence during all treatment cycles. Patients with these risk factors should be carefully monitored for assessment and prophylaxis.
- |||| Halaven (eribulin mesylate) / Eisai, sabizabulin (VERU-111) / Veru Inc
--bulin represents some compounds that inhibit mitotic spindles. Eribulin (Halaven) is an approved drug for breast cancer that is a mitotic spindle inhibitor like Sabizabulin. They share the faintest of structural similarities. Eribulin comes from a sessile sea animal. (Twitter) - Jul 7, 2022
- | Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Metastases: LEADER: Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 5, 2022
P1/2, N=30, Active, not recruiting, Sponsor: National Taiwan University Hospital
Patients with these risk factors should be carefully monitored for assessment and prophylaxis. Trial completion date: Jun 2022 --> Dec 2022
- ||||| Bavencio (avelumab) / EMD Serono, Pfizer, Halaven (eribulin mesylate) / Eisai
Combination therapy: Current Issue: Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study https://t.co/zvtGd1GslA @SheldonLHolder @RohanGarjeMD @DavidDeGraff5 @ZakhariaYousef #carcinoma #urology #MedTwitter (Twitter) - Jul 2, 2022
- | Halaven (eribulin mesylate) / Eisai
Biomarker, Retrospective data, Journal: The Modified Glasgow Prognostic Score and Prognostic Nutritional Index as Prognostic Markers in Patients With Metastatic Breast Cancer Treated With Eribulin. (Pubmed Central) - Jun 30, 2022
Trial completion date: Jun 2022 --> Dec 2022 PNI is a reliable predictor of TTF and OS in patients with MBC treated with eribulin.
- || Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: AIRE: Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer (clinicaltrials.gov) - Jun 30, 2022
P4, N=82, Recruiting, Sponsor: Institut fuer Frauengesundheit
PNI is a reliable predictor of TTF and OS in patients with MBC treated with eribulin. Trial primary completion date: Mar 2022 --> Jan 2023
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, Halaven (eribulin mesylate) / Eisai
Establishment and characterization of a new panel of uterine leiomyosarcoma patient-derived xenograft models (Poster Area) - Jun 28, 2022 - Abstract #EACR2022EACR_1231;
Conclusion We have obtained a panel of uLMS PDXs that mimics the main pathological and molecular features of the original human tumors. The heterogeneity of drug response highlights the need to expand the uLMS PDX panel to identify possible mechanisms of drug resistance and to identify new therapeutic approaches better than the standard of care.
- Halaven (eribulin mesylate) / Eisai
Ovarian carcinosarcoma genomics and preclinical models enable identification of novel mechanisms of action of eribulin (Poster Area) - Jun 28, 2022 - Abstract #EACR2022EACR_700;
These findings not only supporting eribulin for the treatment OCS, but suggesting eribulin/immunotherapy combinations may demonstrate even greater efficacy. As such, we have designed the international EPOCH trial, E ribulin and P embrolizumab in O varian C arcinosarcoma, to improve treatment of this aggressive cancer.
- |||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Halaven (eribulin mesylate) / Eisai
Clinical: Reminder, @DFCI_BreastOnc is leading a study of #coldcaps in patients using trastuzumab deruxtecan, sacituzumab, or eribulin for metastatic breast cancer. Please contact us for any information about the trial! (Twitter) - Jun 27, 2022
- |||| Halaven (eribulin mesylate) / Eisai, gemcitabine / Generic mfg.
Clinical, Combination therapy: Also today @CCR_AACR a third paper on sarcoma! We have been busy! Phase II Clinical Trial of Eribulin–Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma https://t.co/NUEvTASVQE (Twitter) - Jun 21, 2022
- | Halaven (eribulin mesylate) / Eisai
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma (clinicaltrials.gov) - Jun 16, 2022
P2, N=37, Completed, Sponsor: Yonsei University
As such, we have designed the international EPOCH trial, E ribulin and P embrolizumab in O varian C arcinosarcoma, to improve treatment of this aggressive cancer. Trial completion date: Nov 2022 --> May 2022 | Trial primary completion date: Nov 2022 --> May 2022 | Active, not recruiting --> Completed
- | TSL1502 / Tasly
New P2 trial, Metastases: A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations (clinicaltrials.gov) - Jun 14, 2022
P2, N=125, Not yet recruiting, Sponsor: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
- Trodelvy (sacituzumab govitecan-hziy) / Everest Medicines, Gilead
Case report on the use of sacituzumab-govitecan in ER neg. PR pos. metastatic breast cancer with choriocarcinomatous properties (exhibition) - Jun 10, 2022 - Abstract #GSS2022GSS_400;
There was rapid progress from here. A clear remission was achieved with sacituzumab-govitecan.
- || Bavencio (avelumab) / EMD Serono, Pfizer, Halaven (eribulin mesylate) / Eisai
P1 data, Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker: Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study. (Pubmed Central) - Jun 9, 2022
P1b
We observed that treatment was better tolerated and efficacious at lower doses of eribulin. Further research is warranted for this combination in mUC.
- || Trial completion date, Trial primary completion date, Metastases: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Jun 9, 2022
P1/2, N=280, Recruiting, Sponsor: Hoffmann-La Roche
Further research is warranted for this combination in mUC. Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Sep 2023
- |||||| Halaven (eribulin mesylate) / Eisai, Xpovio (selinexor) / Karyopharm, Menarini
P1 data: Truly honored to work with the legends Dr @ANaingMD and Dr Funda Meric-Bernstam to present our #meritaward winning poster: Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer @LabNaing @Karyopharm #ASCO22 @MDAndersonNews (Twitter) - Jun 6, 2022
- || Halaven (eribulin mesylate) / Eisai, gemcitabine / Generic mfg.
I hope those 80 percent who got capcitabine or eribulin or gemcitabine, have got taxens prior. (Twitter) - Jun 6, 2022
- || farletuzumab (MORAB-003) / Eisai, Halaven (eribulin mesylate) / Eisai, farletuzumab ecteribulin (MORAb-202) / Eisai, BMS
#Eisai Presents New Findings for #AntibodyDrugConjugate #FarletuzumabEcteribulin at #ASCO22 https://t.co/NIzh8riXFD (Twitter) - Jun 6, 2022
- ||| Halaven (eribulin mesylate) / Eisai, capecitabine / Generic mfg.
Clinical: I see your point but capecitabine and eribulin are not bad choices, especially in pts not taxane naive, and also the oral delivery makes cape attractive to pts who were just on oral anti HR This is not like the PARPi trials where carbo was deliberately excluded (Twitter) - Jun 5, 2022
- |||| Halaven (eribulin mesylate) / Eisai
Clinical: Probably not ... patients who progressed shortly after adjuvant therapy, which is a concern in historical TNBC, would probably be offered something else - cape and eribulin are both effective tx (Twitter) - Jun 5, 2022
- ||| Halaven (eribulin mesylate) / Eisai
Summary of DESTINY Breast04 Data @NEJM 2022 -small #s of ER neg -50% of TPC chemo was eribulin, only 20% taxane likely b/c of prior treatment - all diffs stat sig at < 0.05 (Twitter) - Jun 5, 2022
- ||| Halaven (eribulin mesylate) / Eisai
Thanks for sharing these important tweets. Curious if you know if the payloads DM4 and Eribulin similar compounds? #gyncsm (Twitter) - Jun 4, 2022
- | Journal: Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. (Pubmed Central) - Jun 4, 2022
For first-line treatment of advanced soft tissue sarcoma in elderly patients, doxorubicin monotherapy is considered to be the standard regimen, and pazopanib can be an alternative. For second-line treatment, gemcitabine-based regimens, pazopanib, trabectedin and eribulin may be options for elderly patients with advanced soft tissue sarcoma.